Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.
Sci Adv. 2017 Nov 22;3(11):eaaq0723. doi: 10.1126/sciadv.aaq0723. eCollection 2017 Nov.
Although previous studies have attempted to create "electronics-free" insulin delivery systems using glucose oxidase and sugar-binding lectins as a glucose-sensing mechanism, no successful clinical translation has hitherto been made. These protein-based materials are intolerant of long-term use and storage because of their denaturing and/or cytotoxic properties. We provide a solution by designing a protein-free and totally synthetic material-based approach. Capitalizing on the sugar-responsive properties of boronic acid, we have established a synthetic polymer gel-based insulin delivery device confined within a single catheter, which exhibits an artificial pancreas-like function in vivo. Subcutaneous implantation of the device in healthy and diabetic mice establishes a closed-loop system composed of "continuous glucose sensing" and "skin layer"-regulated insulin release. As a result, glucose metabolism was controlled in response to interstitial glucose fluctuation under both insulin-deficient and insulin-resistant conditions with at least 3-week durability. Our "smart gel" technology could offer a user-friendly and remarkably economic (disposable) alternative to the current state of the art, thereby facilitating availability of effective insulin treatment not only to diabetic patients in developing countries but also to those patients who otherwise may not be strongly motivated, such as the elderly, infants, and patients in need of nursing care.
虽然之前的研究已经尝试使用葡萄糖氧化酶和糖结合凝集素来创建“无电子”胰岛素输送系统,作为葡萄糖传感机制,但迄今为止尚未成功进行临床转化。由于这些蛋白质材料具有变性和/或细胞毒性,因此它们不能耐受长期使用和储存。我们通过设计一种无蛋白质和完全合成材料的方法提供了一个解决方案。利用硼酸的糖响应特性,我们已经建立了一种基于合成聚合物凝胶的胰岛素输送装置,该装置被限制在单个导管内,在体内表现出类似于人工胰腺的功能。在健康和糖尿病小鼠的皮下植入该装置,建立了一个由“连续葡萄糖感测”和“皮肤层”调节的胰岛素释放组成的闭环系统。结果,在胰岛素缺乏和胰岛素抵抗的情况下,葡萄糖代谢能够响应间质葡萄糖波动进行控制,并且具有至少 3 周的耐久性。我们的“智能凝胶”技术可以为当前的技术提供一种用户友好且经济实惠的(一次性)替代方案,从而不仅为发展中国家的糖尿病患者,而且为那些可能没有强烈动机的患者(如老年人、婴儿和需要护理的患者)提供有效的胰岛素治疗。